Search results
Showing 76 to 90 of 95 results for autologous
MMprofiler for prognostic risk classification in multiple myeloma (MIB270)
NICE has developed a medtech innovation briefing (MIB) on MMprofiler for prognostic risk classification in multiple myeloma .
Extracorporeal shockwave therapy for Achilles tendinopathy (IPG571)
Evidence-based recommendations on extracorporeal shockwave therapy for treating Achilles tendinopathy in adults. This involves passing shockwaves through the skin to the affected area.
NICE's guidance on pancreatic islet cell transplantation has now been replaced. Please go to NICE interventional procedure guidance 257 to view the full guidance on allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus and to NICE interventional procedure guidance 274 to view the full guidance on autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy issued to the NHS in England, Wales, Scotland and Northern Ireland.
This guidance has been updated and replaced by NICE interventional procedure guidance 438.
NICE has developed a medtech innovation briefing (MIB) on PIUR tUS for abdominal aortic aneurysm surveillance and endovascular aneurysm repair endoleak detection .
Multiple myeloma - bortezomib (consolidation therapy) [ID529]
Discontinued Reference number: GID-TAG320
there isn't a short name for any of them. They are: : colposuspension : an autologous rectus fascial sling : a retropubic mid-urethral...
This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.
Autologous cartilage transplantation for full thickness cartilage defects in knee joints (TA16)
This guidance has been replaced by NICE technology appraisal guidance 89 [Replaced by NICE technology appraisal guidance 477].
This guidance has been updated and replaced by NICE technology appraisal guidance 477.
Zanubrutinib for treating Waldenstrom's macroglobulinaemia (TA833)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating Waldenstrom’s macroglobulinaemia in adults.
In development Reference number: GID-TA10843 Expected publication date: TBC
Discontinued Reference number: GID-TA10144
This guidance has been updated and replaced by NICE interventional procedures guidance 793.
In development Reference number: GID-TA10667 Expected publication date: TBC